NCT00410254已完成1 期
An Open Label, Single-Dose Midazolam, Multiple-Dose HCV-796, Sequential 3-Period Study to Determine the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Midazolam
Wyeth is now a wholly owned subsidiary of Pfizer2 个研究点 分布在 1 个国家目标入组 38 人开始时间: 2007年6月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 38
- 试验地点
- 2
- 主要终点
- Safety PK
研究概览
简要总结
To evaluate the potential PK interaction of multiple oral doses of HCV-796 and a single oral dose of midazolam when coadministered to healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy as determined by investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs and 12-lead ECG.
排除标准
- 未提供
结局指标
主要结局
Safety PK
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Study Evaluating the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and DesipramineHealthyNCT00500721Wyeth is now a wholly owned subsidiary of Pfizer22
已完成
1 期
A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and DigoxinHealthy ParticipantsNCT05395117AstraZeneca32
已完成
2 期
Multiple Dose Pharmacokinetics of LCZ696 and Its Metabolites in Subjects With Severe Renal Impairment vs. Matched Healthy Subjects With Normal Renal FunctionPharmacokineticsRenal ImpairedHealthy VolunteerNCT01569828Novartis Pharmaceuticals12
已完成
1 期
Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)Relapsed or Refractory Advanced CancerNCT01071304Merck Sharp & Dohme LLC16
已完成
1 期
Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003)Hepatitis CNCT02269059Merck Sharp & Dohme LLC13